
Two scientists started Dotmatics by making research data easier to use. Stephen Gallagher’s story runs from a spare bedroom in 2005 to an international software business, a leadership handover, and a new chapter helping technical companies grow.

An airline knew his itinerary but still asked him to download an app he already used. A decade after helping build Amperity to close that gap, Kabir Shahani is back at the controls.
Paratus Sciences is a biotechnology company decoding the extreme biology of bats to discover first-in-class medicines. Bats live long, tolerate viruses, resist cancer, control inflammation and thrive on high-sugar diets - traits they evolved over roughly 65 million years. Paratus integrates cell biology, comparative genomics and informatics to translate these adaptations into drug targets for inflammatory and cardiometabolic diseases. Launched in 2023 with a $100M Series A and dual sites in New York and Singapore, its lead program PS-1001 is a first-in-class pan-inflammasome inhibitor.